Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells

Prostate

Volumn 74, Issue 5, 2014, Pages 451-457

  Wu, Lisa Y ^a   Johnson, Jacqueline M ^a   Simmons, Jessica K ^b   Mendes, Desiree E ^a   Geruntho, Jonathan J ^a   Liu, Tiancheng ^a   Dirksen, Wessel P ^b   Rosol, Thomas J ^b   Davis, William C ^a   Berkman, Clifford E ^a,c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Cancer Targeted Technology   (United States)

Author keywords

canine; flow cytometry; inhibitor; prostate cancer; prostate specific membrane antigen (PSMA); RT PCR; substrate; Western blot

Indexed keywords

CANINE; FLOW CYTOMETRY; INHIBITOR; PROSTATE CANCER; PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA); RT-PCR; SUBSTRATE; WESTERN BLOT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; DOGS; ENZYME INHIBITORS; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84894287662     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22727     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Johnston SD, Kamolpatana K, Root-Kustritz MV, Johnston GR,. Prostatic disorders in the dog. Anim Reprod Sci 2000; 60-61: 405-415. (Pubitemid 30397809)
3. Bell FW, Klausner JS, Hayden DW, Feeney DA, Johnston SD,. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987). J Am Vet Med Assoc 1991; 199 (11): 1623-1630.
4. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, Waters DJ,. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: A retrospective analysis of 76 cases. Prostate 2000; 45 (2): 173-183.
5. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC, Tindall DJ,. Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998; 36 (1): 64-67. (Pubitemid 28285643)
6. Waters DJ,. High-grade prostatic intraepithelial neoplasia in dogs. Eur Urol 1999; 35 (5-6): 456-458. (Pubitemid 29229548)
7. Aquilina JW, McKinney L, Pacelli A, Richman LK, Waters DJ, Thompson I, Burghardt WF Jr, Bostwick DG,. High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer. Prostate 1998; 36 (3): 189-193. (Pubitemid 28341131)
8. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, Bostwick DG,. Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate 1997; 30 (2): 92-97. (Pubitemid 27088117)
9. Lai CL, van den Ham R, van Leenders G, van der Lugt J, Mol JA, Teske E,. Histopathological and immunohistochemical characterization of canine prostate cancer. Prostate 2008; 68 (5): 477-488. (Pubitemid 351500208)
10. Thudi NK, Martin CK, Nadella MV, Fernandez SA, Werbeck JL, Pinzone JJ, Rosol TJ,. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate 2008; 68 (10): 1116-1125. (Pubitemid 351875183)
11. Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, Werbeck JL, Simmons JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, Rosol TJ,. Development of a brain metastatic canine prostate cancer cell line. Prostate 2011; 71 (12): 1251-1263.
12. LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, Davis D, Corn S, Rosol TJ,. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 2006; 66 (11): 1213-1222. (Pubitemid 44175343)
13. Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick L, Gu Z, Reiter RE, Bander NH, Rajasekaran AK,. Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate 2003; 55 (1): 9-19. (Pubitemid 36397740)
14. Schmidt S, Fracasso G, Colombatti M, Naim HY,. Cloning and characterization of canine prostate-specific membrane antigen. Prostate 2013; 73 (6): 642-650.
15. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O,. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001; 46 (1): 2-10.
16. Wu LY, Liu T, Grimm AL, Davis WC, Berkman CE,. Flow cytometric detection of prostate tumor cells using chemoaffinity labels. Prostate 2011; 71 (1): 52-61.
17. Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE,. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate 2012; 72 (14): 1532-1541.
18. Senapati S, Chakraborty S, Nath I, Panda SK, Patra RC, Batra SK,. Non-human prostate cancer cell lines. Oncol Gastroenterol Hepatol Rep 2012; 1 (1): 10.
19. Liu T, Wu LY, Kazak M, Berkman CE,. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 2008; 68 (9): 955-964. (Pubitemid 351794160)
20. Liu T, Wu LY, Berkman CE,. Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett 2010; 296 (1): 106-112.
21. Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, Rengifo E, Perez R, Fernandez LE,. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19 (3): 241-247. (Pubitemid 30622625)
22. Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, Holmes EH,. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma 2000; 19 (3): 249-257. (Pubitemid 30622626)
23. Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE,. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 2004; 12 (18): 4969-4979. (Pubitemid 39164405)
24. Wu LY, Anderson MO, Toriyabe Y, Maung J, Campbell TY, Tajon C, Kazak M, Moser J, Berkman CE,. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 2007; 15 (23): 7434-7443. (Pubitemid 47539133)
25. Liu T, Toriyabe Y, Berkman CE,. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 2006; 49 (2): 251-255. (Pubitemid 44416227)
26. Anderson MO, Wu LY, Santiago NM, Moser JM, Rowley JA, Bolstad ES, Berkman CE,. Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 2007; 15 (21): 6678-6686. (Pubitemid 47385247)
27. Liu T, Toriyabe Y, Kazak M, Berkman CE,. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 2008; 47 (48): 12658-12660.
28. Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF,. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 2009; 50 (12): 2042-2048.
29. Nedrow-Byers JR, Jabbes M, Jewett C, Ganguly T, He H, Liu T, Benny P, Bryan JN, Berkman CE,. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate 2011; 72 (8): 904-912.